Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline and E-cigarettes for Tobacco Harm Reduction
NCT04210180Phase 3Completed
- Sponsor
- Rose Research Center
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of varenicline in Tobacco Use Disorder (TUD), sponsored by Rose Research Center. Primary endpoints: Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6 and Number of Participants Confirmed (by Expired Air CO) to Have Switched From Cigarettes to Halo G6. Started Nov 2019; status: completed.
02
Drugs
varenicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04210180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210180.